ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vaccination"

  • Abstract Number: 1551 • ACR Convergence 2021

    Generation of Autoantibodies and Their Association with Rheumatic Disease Flares in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases and General Adult Population Following BNT162b2 mRNA Covid-19 Vaccination

    Tal Gazitt1, Joy Feld2, Amir Haddad3, Muna Elias4, Nizar Hijazi4, Nili Stein4, Victoria Furer5, Tali Eviatar6, Hagit Peleg7, Ori Elkayam8 and Devy Zisman4, 1Carmel Hospital, Haifa, Israel, 2Carmel and Zvulun Medical Centre, Haifa, Israel, 3Carmel Medical Centre, Haifa, Israel, 4Carmel Medical Center, Haifa, Israel, 5Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 6Tel Aviv Sourasky Medical Center, Givataim, Israel, 7Hadassah Medical Center, Jerusalem, Israel, 8Tel Aviv Medical Center, Tel Aviv, Israel

    Background/Purpose: The rapid spread of the COVID-19 pandemic has created the need for mass vaccination of patients with autoimmune rheumatic disease (AIIRD) despite the lack…
  • Abstract Number: 1562 • ACR Convergence 2021

    B Cell Reconstitution Is Strongly Associated with COVID-19 Vaccine Responsiveness in Rheumatic Disease Patients Treated with Rituximab

    Sarah Jinich, Deanna Jannat-Khah and Robert Spiera, Hospital for Special Surgery, New York, NY

    Background/Purpose: Rituximab (RTX) has previously been shown to impair antibody response to vaccines such as influenza and streptococcus. Recently, diminished COVID-19 vaccine responsiveness in RTX…
  • Abstract Number: 0104 • ACR Convergence 2021

    Adverse Events of First SARS-CoV-2 Vaccinations Are Comparable for Patients with Autoimmune Diseases and the General Population

    Laura Boekel1, Laura Kummer2, Koos van Dam2, Femke Hooijberg1, Zoé van Kempen2, Erik Vogelzang2, Luuk Wieske2, Filip Eftimov2, Ronald van Vollenhoven3, Taco Kuijpers2, Marieke van Ham4, Sander Tas5, Joep Killestein2, Maarten Boers6, Mike Nurmohamed7, Theo Rispens4 and Gertjan Wolbink1, 1Reade, Amsterdam, Netherlands, 2Amsterdam UMC, Amsterdam, Netherlands, 3Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 4Sanquin, Amsterdam, Netherlands, 5Amsterdam UMC, locatie AMC, Utrecht, Netherlands, 6Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 7Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands

    Background/Purpose: Clinical trials on efficacy and safety of SARS-CoV-2 vaccines did not include patients with autoimmune diseases. We previously demonstrated that concerns of adverse events…
  • Abstract Number: 1589 • ACR Convergence 2021

    COVID-19 Vaccine Hesitancy in Rheumatology Patients

    Rebecca Sadun1, Amanda Eudy1, Jennifer Rogers1, Kai Sun2, Lisa Criscione-Schreiber2, Mithu Maheswaranathan2, Jayanth Doss1 and Megan Clowse3, 1Duke University, Durham, NC, 2Duke University School of Medicine, Durham, NC, 3Duke University, Chapel Hill, NC

    Background/Purpose: Patients with rheumatic diseases on certain immunosuppressant medications are known to be at higher risk for severe COVID-19. The ACR recommends COVID-19 vaccination for…
  • Abstract Number: 0113 • ACR Convergence 2021

    Reactogenicity of the SARS-CoV-2 Vaccines Associates with Immunogenicity in Patients with Autoimmune and Inflammatory Disease

    Monica Yang1, Kimberly E. Taylor1, Diana Paez1, Alex Carividi1, Emanuel Demissie1, Niti Pawar1, Alia A. El-Qunni,2, Lily E. McMorrow2, Rebecca E. Schriefer2, Katherine Huang2, Baylee Kinnett2, Wooseob Kim2, Ali H Ellebedy2, Matthew Ciorba2, Michael Paley3, Parakkal Deepak2, Alfred Kim2, Patricia Katz1, Mehrdad Matloubian1, Mary Nakamura4 and Lianne Gensler5, 1University of California San Francisco, San Francisco, CA, 2Washington University School of Medicine, St. Louis, MO, 3Washington University in St. Louis, Olivette, MO, 4UCSF/SFVAHCS, San Francisco, CA, 5Department of Rheumatology, University of California San Francisco, San Francisco, CA

    Background/Purpose: Little is known about the reactogenicity and related SARS-CoV-2 vaccine response in patients with chronic inflammatory disease (CID). While researchers have hypothesized increased symptomatology…
  • Abstract Number: 1603 • ACR Convergence 2021

    COVID-19 Vaccination Experience in Patients with Rheumatoid Arthritis Treated at the Cleveland VA Medical Center

    Sarah Abi Doumeth1, Laura Silversteyn2, Donald Anthony2 and Maya Mattar3, 1University hospitals Cleveland medical center, Cleveland, OH, 2Louis Stokes Cleveland VA Medical Center, Cleveland, OH, 3Louis Stokes VA Medical Center, Mayfield Heights, OH

    Background/Purpose: Following the introduction of the COVID-19 vaccines, there has been uncertainty as to whether receiving the COVID-19 vaccine would result in overactivation of the…
  • Abstract Number: 0390 • ACR Convergence 2021

    Vaccination Against COVID-19: Self-Reported Experiences of Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort

    Kimberly Showalter1, Jessica Gordon1, Yin Wu2, Linda Kwakkenbos3, Marie-Eve Carrier4, Richard Henry2, Nora Østbø2, Julia Nordlund2, Angelica Bourgeault2, Mara Canedo Ayala2, Marie-Nicole Discepola2, Andrea Carboni Jiménez2, Christopher Denton5, Luc Mouthon6, Brett Thombs7 and Robert Spiera1, 1Hospital for Special Surgery, New York, NY, 2Lady Davis Institute of the Jewish General Hospital, Montréal, QC, Canada, 3Department of Clinical Psychology, Radboud University Behavioural Science Institute, Nijmegen, Netherlands, 4Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, 5University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, 6Centre de Référence Maladies Autoimmunes Systémiques Rares d'Ile de France, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, 7Lady Davis Institute for Medical Research, Jewish General Hospital; Department of Psychiatry, McGill University, Montréal, QC, Canada

    Background/Purpose: COVID-19 vaccination is recommended for individuals with rheumatic diseases, yet data are limited regarding vaccine safety in this population, particularly among those with rare…
  • Abstract Number: 1607 • ACR Convergence 2021

    The Impact of Health Literacy and Numeracy on COVID-19 Vaccine Hesitancy in SLE

    Rebecca Sadun1, Mithu Maheswaranathan1, Megan Clowse2, Kai Sun1, Jennifer Rogers1, Jayanth Doss1, Lisa Criscione-Schreiber3 and Amanda Eudy1, 1Duke University, Durham, NC, 2Duke University, Chapel Hill, NC, 3Duke University School of Medicine, Durham, NC

    Background/Purpose: The ACR has issued guidance recommending COVID-19 vaccine for all patients with rheumatic diseases. Vaccine hesitancy research prior to the COVID-19 pandemic has demonstrated…
  • Abstract Number: 0457 • ACR Convergence 2021

    Immunosuppression Attenuates Antibody and Neutralization Titers in Patients with Chronic Inflammatory Disease Following SARS-CoV-2 Vaccination

    Michael Paley1, Parakkal Deepak2, Wooseob Kim2, Monica Yang3, Alex Carividi3, Emanuel Demissie3, Alia A. El-Qunni,2, Alem Haile2, Katherine Huang2, Baylee Kinnett2, Mariel Liebeskind2, Zhouming Liu2, Lily E. McMorrow2, Diana Paez3, Niti Pawar3, Dana Perantie2, Rebecca E. Schriefer2, Shannon Sides2, Mahima Thapa2, Sewuese Akuse4, Samantha Burdess2, Abbey Rose2, Lynne Mitchell2, Salim Chahin2, Matthew Ciorba2, Jonathan Graf5, Patricia Katz3, Mehrdad Matloubian3, Jane O'Halloran2, Rachel Presti2, Gregory Wu2, Sean Whelan2, William Buchser2, Lianne Gensler6, Mary Nakamura7, Ali H Ellebedy2 and Alfred Kim2, 1Washington University in St. Louis, Olivette, MO, 2Washington University School of Medicine, St. Louis, MO, 3University of California San Francisco, San Francisco, CA, 4Washington University School of Medicine, St Louis, MO, 5Ucsf, San Francisco, CA, 6Department of Rheumatology, University of California San Francisco, San Francisco, CA, 7UCSF/SFVAHCS, San Francisco, CA

    Background/Purpose: Individuals with chronic inflammatory diseases (CID) are frequently treated with immunosuppressive medications that can increase their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2…
  • Abstract Number: 1616 • ACR Convergence 2021

    Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley

    Sukesh Sukumaran1, Reshma Patel2 and Deepika Singh3, 1Valley Children's Healthcare, Madera, CA, 2Valley Children's Hospital, Madera, CA, 3Valley Children Healthcare, Madera, CA

    Background/Purpose: The U.S. FDA has expanded the emergency use authorization of the COVID-19 vaccine to include children >12 years of age. Gaining an understanding of…
  • Abstract Number: 0640 • ACR Convergence 2021

    Implementation of Digital Prompt in Electronic Medical Records Improves Pneumonia Vaccination Rates in Patients Prescribed TNF-Inhibitors

    Manjeet Bhamra1 and Andras Perl2, 1SUNY Upstate Medical University, Syracuse, NY, 2State University of New York, Syracuse, NY

    Background/Purpose: Tumor necrosis factor α inhibitors (TNFi) predispose to bacterial infections including pneumonia. In turn, vaccination with pneumococcal 13 valent (PCV13) and pneumococcal 23 valent…
  • Abstract Number: 1843 • ACR Convergence 2021

    Perceptions and Concerns Regarding COVID-19 Vaccination in Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort

    Jessica Gordon1, Kimberly Showalter1, Yin Wu2, Linda Kwakkenbos3, Marie-Eve Carrier4, Richard Henry2, Nora Østbø2, Julia Nordlund2, Angelica Bourgeault2, Mara Canedo Ayala2, Marie-Nicole Discepola2, Andrea Carboni Jiménez2, Christopher Denton5, Luc Mouthon6, Brett Thombs7 and Robert Spiera1, 1Hospital for Special Surgery, New York, NY, 2Lady Davis Institute of the Jewish General Hospital, Montréal, QC, Canada, 3Department of Clinical Psychology, Radboud University Behavioural Science Institute, Nijmegen, Netherlands, 4Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, 5University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, 6Hopital Cochin - Paris University, Paris, France, 7Lady Davis Institute for Medical Research, Jewish General Hospital; Department of Psychiatry, McGill University, Montréal, QC, Canada

    Background/Purpose: Hesitancy about COVID-19 vaccination exists among patients with rheumatic and musculoskeletal diseases, but previous studies have not assessed this specifically in patients with systemic…
  • Abstract Number: 0649 • ACR Convergence 2021

    Optimizing SARS-CoV-2 Vaccine Timing in Rituximab-Treated Patients with Autoimmune Rheumatic Diseases: A Quality Improvement Intervention

    Daniel Magliulo1, Stefanie Wade2 and Vasileios Kyttaris3, 1Beth Israel Deaconess Medical Center, Boston, MA, 2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3BIDMC, Boston, MA

    Background/Purpose: Experience with rituximab (RTX) in autoimmune rheumatic disease (AIRD) has shown a clear association with hypogammaglobulinemia, serious infections, and impaired humoral response to certain…
  • Abstract Number: 0964 • ACR Convergence 2021

    Rituximab Treatment Dramatically Reduces Neutralizing Humoral Response to mRNA SARS-COV-2 Vaccines in Patients with Autoimmune Diseases

    Samuel Bitoun1, Julien Henry2, Christelle Vauloup Fellous3, Raphaele Seror4, Lina Mouna3, Candie Joly5, Delphine Desjardins5, Marie Bitu5, Roger Le Grand6, Anne-Marie Roque Afonso3 and Xavier Mariette7, 1Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184 FHU CARE, Paris, France, 2Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184 FHU CARE, Le Plessis Robinson, France, 3AP–HP, Hôpital Paul-Brousse, Department of Virology, University Paris Saclay, INSERM U1193,, Villejuif, France, 4Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184, FHU CARE FHU CARE, Le kremlin Bicetre, France, 5Paris-Saclay University, Inserm UMR 1184, FHU CARE, CEA, Le Kremlin Bicêtre, France, 6UMR1184, IDMIT Department, Université Paris-Saclay, Inserm, CEA, Fontenay Aux Roses, France, 7Université Paris- Saclay, Rheumatology, Paris, France

    Background/Purpose: The global COVID-19 pandemic is starting to be controlled by massive vaccination. Some immunosuppressed patients have already paid a high price to the pandemic…
  • Abstract Number: 0983 • ACR Convergence 2021

    Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study

    Andrea Rubbert-Roth1, Nicolas Vuilleumier2, Burkhard Ludewig3, Kristin Schmiedeberg4, Yella Rottlaender4, Ian Pirker5 and Johannes VonKempis6, 1Kantonspital St Gallen, St.Gallen, Switzerland, 2Departement Diagnostique, University of Geneva, Switzerland, Geneva, Switzerland, 3Institute of Immunobiology, Cantonal Hospital St Gallen, St Gallen, Switzerland, 4Division of Rheumatology, Cantonal Hospital St Gallen, St Gallen, Switzerland, 5Kantonsspital St. Gallen, St.Gallen, Switzerland, 6Division of Rheumatology and Immunology, St. Gallen, Switzerland

    Background/Purpose: Long-term vaccine-induced immunity to SARS-CoV-2 is critical to combat the pandemic. Vaccination against anti SARS-CoV-2 is recommended in patients with rheumatic diseases, but limited…
  • 1
  • 2
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology